JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Начало・Списък с акции・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Затворен

4.64 -5.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.55

Максимум

4.75

Ключови измерители
By Trading Economics
P/E Средно за сектора	1.717 37.461
EPS	-0.43
Служители	8

Дивиденти
By Dow Jones
Следващи печалби	3.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	5.4M 15M
Предишно отваряне	9.95
Предишно затваряне	4.64

Minerva Neurosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.10.2025 г., 15:58 ч. UTC

Значими двигатели на пазара

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Сравнение с други в отрасъла

Ценова промяна

Minerva Neurosciences Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Minerva Neurosciences Inc през последните 3 месеца.

Финанси

Относно Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.